Major finding:ROS1 chromosomal rearrangements define a molecular subtype of NSCLC.

Impact:ROS1 rearrangements tend to occur in younger, non-smoking NSCLC patients.

Clinical relevance:ROS1-positive NSCLC patients may benefit from crizotinib therapy.

This content is only available via PDF.